Literature DB >> 18611526

ARI 1: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii.

R Paton1, R S Miles, J Hood, S G Amyes, R S Miles, S G Amyes.   

Abstract

A strain of Acinetobacter baumannii 6B92 isolated from the blood culture of a patient at the Edinburgh Royal Infirmary i 1985 was found to be resistant to imipenem, all classes of cephalosporins and penicillins. Extraction of the soluble proteins of the cell and isoelectric focusing revealed the presence of two beta-lactamases: a chromosomal cephalosporinase of high pI (> pI 9.0) and a novel beta-lactomase of pI 6.65 named ARI 1 (Acinetobacter resistant to imipenem). Despite the fact that original clinical isolate could be 'cured' of its resistance to imipenem and penicillins by growing in the presence of ethidium bromide with the concurrent loss of the ARI 1 enzymes, no resistance plasmid was visualised or transferred. The ARI 1 beta-lactamase hydrolysed penicillin, ampicillin and cephaloridine slowly during enzyme assay but inactivation of imipenem could only be demonstrated by microbiological means. The molecular size of the ARI 1 enzyme was 23 kDa and it was not inhibited by EDTA, p-CMB, or clavulanate.

Entities:  

Year:  1993        PMID: 18611526     DOI: 10.1016/0924-8579(93)90045-7

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  74 in total

1.  Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92.

Authors:  H M Donald; W Scaife; S G Amyes; H K Young
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

2.  Emergence of carbapenem-hydrolyzing enzymes in Acinetobacter baumannii clinical isolates.

Authors:  G J Da Silva; G J Leitão; L Peixe
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

3.  Detection of carbapenemase-producing Acinetobacter baumannii in a hospital.

Authors:  A Takahashi; S Yomoda; I Kobayashi; T Okubo; M Tsunoda; S Iyobe
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC beta-lactamase in Acinetobacter baumannii.

Authors:  G Bou; J Martínez-Beltrán
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 5.  Beta-lactamase nomenclature.

Authors:  George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals.

Authors:  Maria Virginia Villegas; Juan Nicolas Kattan; Adriana Correa; Karen Lolans; Ana Maria Guzman; Neil Woodford; David Livermore; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

7.  OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii.

Authors:  Laurent Poirel; Sophie Marqué; Claire Héritier; Christine Segonds; Gérard Chabanon; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

8.  Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil.

Authors:  Libera M Dalla-Costa; Juliana M Coelho; Helena A P H M Souza; Maria E S Castro; Christiane J N Stier; Karin L Bragagnolo; Alvaro Rea-Neto; Sergio R Penteado-Filho; David M Livermore; Neil Woodford
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Crystal structure of carbapenemase OXA-58 from Acinetobacter baumannii.

Authors:  Clyde A Smith; Nuno Tiago Antunes; Marta Toth; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

10.  Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain.

Authors:  S López-Hernández; T Alarcón; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.